US 9,353,157 B2Granted

Influenza inhibiting compositions and methods

AssigneesThe Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC

InventorsRobert F. Garry, Russell B. Wilson

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.

Claims25

Dependent claims

A pharmaceutical composition for treating an influenza infection comprising a pharmaceutically acceptable carrier containing an isolated peptide, wherein the amino acid sequence of the isolated peptide is selected from the group consisting of SEQ ID NO:

3, SEQ ID NO:
4, SEQ ID NO:
5, SEQ ID NO:
6, SEQ ID NO:
7, SEQ ID NO:
8, SEQ ID NO:
9, SEQ ID NO:
10, SEQ ID NO:
11, SEQ ID NO:
12, SEQ ID NO:
13, and a variant of SEQ ID NO:3 including one or more amino acid substitutions in said amino acid sequence selected from the group consisting of V1I, V1L, V1A, V1G, V1T, V1S, V1M, E2D, E2K, E2R, D3E, T4G, T4S, T4Q, T4N, K5F, K5M, K5I, K5V, K5L, K5A, I6L, I6V, I6A, I6T, I6S, I6Q, I6N, D7E, L8I, L8V, L8A, W9Y, S10T, S10G, S10A, and S10M, the variant comprising the sequence YNAELL (SEQ ID NO:
1) and sharing at least 50 percent sequence identity with SEQ ID NO:
3.

10 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/101,452Filed 10 Dec 2013 · continuation
Priority: 25 Jun 2007
Published: US 2014/0194347 A110 Jul 2014
Granted: 31 May 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
A61K 38/04
Medicinal preparations containing peptides: peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 38/10
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 12 to 20 amino acids
A61K 39/145
Viral antigens: orthomyxoviridae, e.g. influenza virus

Family

Application60/937,120Us provisional application · filed 25 Jun 2007
PCT/US2008/007918Parent of this continuation · filed 25 Jun 2008
US 8,604,165 B2Parent of this continuation · filed 10 Dec 2013
US 2014/0194347 A1Pre-grant publication · published 10 Jul 2014
Application12/452,240Parent of this continuation
US 2010/0152109 A1Published application
US 9,353,157 B2This patent

From the US filing history. Foreign family members aren’t listed.